PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 16, 2026ESMO Open2 citationsOpen Access

Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer: a meta-analysis

View Full Paper
WSW.K. SchwengberRPR.A. PereiraLSL.F. Leite da Silva

Key Points

  • This research evaluates the effectiveness and safety of neoadjuvant immune checkpoint inhibitors in localized dMMR/MSI-H gastric cancer.
  • Conducted a meta-analysis of existing studies on neoadjuvant immune checkpoint inhibitors in gastric cancer.
  • Analyzed efficacy and safety data, focusing on pathological complete response rates and treatment duration.
  • Examined the potential of organ-preserving strategies.
  • Neoadjuvant immune checkpoint inhibitors are linked to favorable efficacy and safety outcomes.
  • Longer treatment duration (≥3 months) correlates with improved pathological complete response rates.
  • The need for larger prospective studies is emphasized to determine optimal treatment protocols.

Abstract

Neoadjuvant ICIs are associated with favorable efficacy and safety in localized dMMR/MSI-H gastric and GEJ cancers. Longer neoadjuvant exposure (≥3 months) may improve pCR rates. Larger prospective studies are needed to define optimal treatment duration and the role of organ-preserving strategies such as NOM.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schwengber et al. (2026) studied this question.

synapsesocial.com/papers/6992b3769b75e639e9b0827chttps://doi.org/10.1016/j.esmoop.2026.106066
Ask AI
Helpful
Bookmark
Share
View Full Paper